Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab versus methotrexate for moderate chronic plaque psoriasis
ISRCTN18260393Phase 3Recruiting
- Sponsor
- Newcastle Clinical Trials Unit
- Start
- Sep 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in psoriasis comparing Adalimumab with Methotrexate control (2 arms). Primary endpoints: PASI 75 at 16 weeks and Incremental cost per QALY gained at 24 weeks. Started Sep 2026; status: recruiting.
02
Drugs
adalimumabmethotrexate
03
Conditions
psoriasis
Beyond the preview
Go deeper on ISRCTN18260393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN18260393.